Cargando…

Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes

BACKGROUND: The most common drug abuse among athletes is anabolic steroids which lead to the development of cardiovascular diseases and sudden death. Thus, the aim of this study was to evaluate cardiovascular outcomes of anabolic consumption in body building athletes. MATERIALS AND METHODS: Totally,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gheshlaghi, Farzad, Piri-Ardakani, Mohammad-Reza, Masoumi, Gholam Reza, Behjati, Mohaddaseh, Paydar, Parva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400712/
https://www.ncbi.nlm.nih.gov/pubmed/25983770
_version_ 1782367070096195584
author Gheshlaghi, Farzad
Piri-Ardakani, Mohammad-Reza
Masoumi, Gholam Reza
Behjati, Mohaddaseh
Paydar, Parva
author_facet Gheshlaghi, Farzad
Piri-Ardakani, Mohammad-Reza
Masoumi, Gholam Reza
Behjati, Mohaddaseh
Paydar, Parva
author_sort Gheshlaghi, Farzad
collection PubMed
description BACKGROUND: The most common drug abuse among athletes is anabolic steroids which lead to the development of cardiovascular diseases and sudden death. Thus, the aim of this study was to evaluate cardiovascular outcomes of anabolic consumption in body building athletes. MATERIALS AND METHODS: Totally, 267 male athletes at the range of 20-45 years old with the regular consumption of anabolic steroids for >2 months with at least once weekly. High-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and hematocrit (Hct) levels were measured after 10 h of fasting. Data analysis was performed using K2, t-test, ANOVA and correlation coefficient through SPSS 17. RESULTS: There was a nonsignificant difference between groups regarding HDL, TG, and total cholesterol. There was a significant decrease in the total and categorized LDL and Hct levels in consumers of anabolic steroid versus nonusers (P = 0.01 and P = 0.041, respectively). Results showed a significant increase in systolic and diastolic blood pressure (SBP and DBP) in anabolic steroid users which associates with duration of abuse (P = 0.02 and P = 0.03, respectively). No significant electrocardiography changes were found within the follow-up period. CONCLUSION: Increase in SBP or DBP is a common complication of these drugs which can lead serious vascular disorders. The lower LDL cholesterol level might be due to the higher amounts of lipid consumption in these athletes.
format Online
Article
Text
id pubmed-4400712
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-44007122015-05-15 Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes Gheshlaghi, Farzad Piri-Ardakani, Mohammad-Reza Masoumi, Gholam Reza Behjati, Mohaddaseh Paydar, Parva J Res Med Sci Original Article BACKGROUND: The most common drug abuse among athletes is anabolic steroids which lead to the development of cardiovascular diseases and sudden death. Thus, the aim of this study was to evaluate cardiovascular outcomes of anabolic consumption in body building athletes. MATERIALS AND METHODS: Totally, 267 male athletes at the range of 20-45 years old with the regular consumption of anabolic steroids for >2 months with at least once weekly. High-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and hematocrit (Hct) levels were measured after 10 h of fasting. Data analysis was performed using K2, t-test, ANOVA and correlation coefficient through SPSS 17. RESULTS: There was a nonsignificant difference between groups regarding HDL, TG, and total cholesterol. There was a significant decrease in the total and categorized LDL and Hct levels in consumers of anabolic steroid versus nonusers (P = 0.01 and P = 0.041, respectively). Results showed a significant increase in systolic and diastolic blood pressure (SBP and DBP) in anabolic steroid users which associates with duration of abuse (P = 0.02 and P = 0.03, respectively). No significant electrocardiography changes were found within the follow-up period. CONCLUSION: Increase in SBP or DBP is a common complication of these drugs which can lead serious vascular disorders. The lower LDL cholesterol level might be due to the higher amounts of lipid consumption in these athletes. Medknow Publications & Media Pvt Ltd 2015-02 /pmc/articles/PMC4400712/ /pubmed/25983770 Text en Copyright: © Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Gheshlaghi, Farzad
Piri-Ardakani, Mohammad-Reza
Masoumi, Gholam Reza
Behjati, Mohaddaseh
Paydar, Parva
Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes
title Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes
title_full Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes
title_fullStr Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes
title_full_unstemmed Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes
title_short Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes
title_sort cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400712/
https://www.ncbi.nlm.nih.gov/pubmed/25983770
work_keys_str_mv AT gheshlaghifarzad cardiovascularmanifestationsofanabolicsteroidsinassociationwithdemographicvariablesinbodybuildingathletes
AT piriardakanimohammadreza cardiovascularmanifestationsofanabolicsteroidsinassociationwithdemographicvariablesinbodybuildingathletes
AT masoumigholamreza cardiovascularmanifestationsofanabolicsteroidsinassociationwithdemographicvariablesinbodybuildingathletes
AT behjatimohaddaseh cardiovascularmanifestationsofanabolicsteroidsinassociationwithdemographicvariablesinbodybuildingathletes
AT paydarparva cardiovascularmanifestationsofanabolicsteroidsinassociationwithdemographicvariablesinbodybuildingathletes